Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Groenwold RH, Klungel OH, Altman DJ, van der Graaf Y, Hoes AW, Moons KG, Rivero E, Fortuny J, PROTECT WP2. Adjustment for continuous confounders: an example of how to prevent residual confounding. Can Med Assoc J. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J. 2011 Apr 1;183(7):E411-9.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Mosconi M, Nelson LM, Hooper SR. Confirmatory Factor Analysis of the NEPSY for younger and older school-age children. Psychol Rep. 2008 Jun;102(3):861-6.